Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, Kalofonos H, Fountzilas G, Panagiotou P, Kokkalis G, Papadopoulos O, Castana O, Papadopoulos S, Stavrinidis E, Vourli G, Ioannovich J, Gogas H. Pectasides D, et al. Among authors: kalofonos h. J Clin Oncol. 2009 Feb 20;27(6):939-44. doi: 10.1200/JCO.2008.16.3121. Epub 2009 Jan 12. J Clin Oncol. 2009. PMID: 19139440 Clinical Trial.
Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Janinis J, Stathopoulos GP, Nikolaidis P, Kalofonos HP, Kalogera-Fountzila A, Samantas E, Aravantinos G, Anagnostopoulos A, Tolis C, Makatsoris T, Rigatos SK, Bafaloukos D, Dimopoulos MA, Daniilidis J, Fountzilas G. Janinis J, et al. Anticancer Drugs. 2004 Jun;15(5):479-87. doi: 10.1097/01.cad.0000127662.81719.86. Anticancer Drugs. 2004. PMID: 15166622 Clinical Trial.
Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
Gogas H, Bafaloukos D, Ioannovich J, Skarlos D, Polyzos A, Fountzilas G, Kalofonos HP, Aravantinos G, Tsoutsos D, Panagiotou P, Frangia K, Petrakopoulou T, Pectasides D; Hellenic Coperative Oncology Group. Gogas H, et al. Among authors: kalofonos hp. Anticancer Res. 2004 May-Jun;24(3b):1947-52. Anticancer Res. 2004. PMID: 15274382 Free article. Clinical Trial.
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Fountzilas G, Christodoulou C, Tsavdaridis D, Kalogera-Fountzila A, Aravantinos G, Razis E, Kalofonos HP, Papakostas P, Karina M, Gogas H, Skarlos D. Fountzilas G, et al. Among authors: kalofonos hp. Cancer Invest. 2004;22(5):655-62. doi: 10.1081/cnv-200032980. Cancer Invest. 2004. PMID: 15581045 Clinical Trial.
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, Mavroudis D, Briasoulis E, Pavlidis N, Razis E, Kosmidis P, Gogas H. Fountzilas G, et al. Among authors: kalofonos hp. Breast Cancer Res Treat. 2005 Jul;92(1):1-9. doi: 10.1007/s10549-005-0322-y. Breast Cancer Res Treat. 2005. PMID: 15980985 Clinical Trial.
The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
Samelis GF, Kalofonos H, Adamou A, Kosmides P, Skarlos D, Aravantinos G, Kiamouris C, Adimchi O, Fountzilas G, Dimopoulos AM. Samelis GF, et al. Among authors: kalofonos h. Urology. 2005 Aug;66(2):382-5. doi: 10.1016/j.urology.2005.02.023. Urology. 2005. PMID: 16098366 Clinical Trial.
378 results